Brad Briggs is the Executive Editor of StreetAuthority.com, StreetAuthority Insider. As Executive Editor, Brad manages the team of writers and editors responsible for our two free newsletters, StreetAuthority Daily and Dividend Opportunities as well as all of the free articles on our website, StreetAuthority.com. He is also the managing editor and a regular contributor for StreetAuthority's subscriber-only newsletter, StreetAuthority Insider. Brad joined StreetAuthority in 2008 and has used his journalism training to research and identify opportunities for investors ranging from energy to deep value to momentum plays. Dozens of his articles have been featured on Yahoo Finance, Nasdaq.com and MSN Money, among others. Brad combines his years of experience in the financial industry along with a deep study of behavioral economics and investor psychology to stress the importance of minimizing the role of emotion in trading. Brad is a graduate of Baylor University and has received numerous individual and staff awards from the Society of Professional Journalists, the Texas Intercollegiate Press Association and the Houston Press Club. When not tracking the markets, Brad also enjoys traveling the world.
Analyst Articles
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings...
Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings season, while the S&P is up +10% for the year. The market couldn’t have made it to this...
Read More
The largest savings and loan in the United States said second-quarter earnings were up 16% from last year. Net income rose to $127.9 million, or 26 cents a share, compared with $110.7 million, or 22 cents a… Read More
Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
Healthcare giant Johnson & Johnson (NYSE: JNJ) said this morning that second-quarter earnings amounted to $1.15 a share. The results, a -4.7% decline from a year ago, beat expectations, despite challenges facing the company’s pharmaceutical unit and a stronger dollar. The company said… Read More
A key measure of wholesale prices rose in June at nearly twice the increase economists had forecast. It was the sharpest rise for the index since November 2007. The Producer Price Index, which tracks how much it costs for manufacturers to make things,… Read More
The first half of 2009 has been nothing short of volatile for Wall Street. Between corporate bailouts, bankruptcies and unprecedented government spending, the news has been full of surprises. The assorted high-profile shenanigans of GM, AIG and others deserve their rightful place in the “Hall of Shame,” but there has… Read More
Nathan, some investors may feel we’ve found ourselves in uncharted territory during this market, but you seem to think value investors should be salivating right now. Why? Nathan Slaughter: There are always bargains to be had in the market. Unfortunately, during normal conditions value hunters looking for deeply underpriced… Read More
